Compare VEEE & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VEEE | JAGX |
|---|---|---|
| Founded | 1994 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 2.2M |
| IPO Year | 2021 | 2014 |
| Metric | VEEE | JAGX |
|---|---|---|
| Price | $26.40 | $1.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | ★ 4.1M | 56.3K |
| Earning Date | 05-08-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.42 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,819,130.00 | $11,511,000.00 |
| Revenue This Year | $3.24 | $61.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.99 | N/A |
| 52 Week Low | $0.14 | $0.22 |
| 52 Week High | $48.79 | $8.00 |
| Indicator | VEEE | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 68.48 | 33.54 |
| Support Level | $1.99 | $1.68 |
| Resistance Level | N/A | $1.98 |
| Average True Range (ATR) | 6.17 | 0.20 |
| MACD | 3.08 | -0.08 |
| Stochastic Oscillator | 52.60 | 0.00 |
Twin Vee PowerCats Co is a designer, manufacturer, and marketer of recreational and commercial power boats to use for fishing, diving and water skiing, and commercial activities including transportation, eco-tours, fishing, and diving expeditions. The company offers various boat models, including Twin Vee 400 GFX2 CC, Twin Vee 280 GFX2 CC, and Twin Vee 260 Center Console STX, among others. Its products are marketed under two brands, Twin Vee for its catamarans, or dual-hull vessels, and Aquasport for its V-hull boats. The company sells its boats through a network of independent boat dealers across North America, the Caribbean, and Central America who resell the boats to the end user, Twin Vee customers.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.